A Phase 3, Randomized, Double Blind, Placebo Controlled,

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor Monotherapy
StatusFinished
Effective start/end date1/31/131/31/16

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.